1. Introduction: The Unfashionable Lifesaver
No intervention in the history of medicine has saved more life-years than vaccination. A 2024 modelling analysis published in The Lancet estimated that the WHO Expanded Programme on Immunization, since its launch in 1974, has averted approximately 154 million deaths, the great majority in children under five, and has accounted for roughly 40% of the global decline in infant mortality over that period (Shattock et al., 2024). Smallpox has been eradicated; polio is close; measles, Haemophilus influenzae type b meningitis, and other once-common killers have been pushed to the margins wherever coverage is high.
Preventive medicine more broadly — blood-pressure checks, lipid panels, cancer screening, diabetes testing, hepatitis C testing — converts sudden catastrophe into manageable findings. For longevity the logic is elementary and strategic: one cannot benefit from future rejuvenation technologies without surviving the preventable threats that would otherwise remove the option. This article examines vaccination and screening in turn, distinguishing the strong randomized and quasi-experimental evidence from the associative, and foregrounding the areas — immunosenescence, off-target vaccine effects, overdiagnosis — where the picture is genuinely contested.
2. How Vaccines Work and Why Older Adults Respond Differently
Vaccines generate immunological memory — long-lived antibody-secreting plasma cells and memory B and T cells — without the risks of natural infection. Their performance depends on both the vaccine (live-attenuated, inactivated, subunit, conjugate, mRNA, viral-vector) and the host. This host dependence becomes decisive at older ages.
Immunosenescence is the age-related decline of adaptive immunity: reduced output of naive T cells from an involuting thymus, a pro-inflammatory baseline («inflammaging»), and blunted germinal-centre responses. The practical consequences are lower seroconversion rates, more rapid waning of antibody titres, and reduced clinical efficacy in the very age group at greatest risk of severe outcomes. This is why several vaccines are reformulated for older adults: higher antigen doses (high-dose influenza vaccine), immune adjuvants (adjuvanted influenza and recombinant zoster vaccines), and conjugate chemistry that induces T-cell help (pneumococcal conjugate). The general principle is established; the optimal schedule and the relative value of each strategy in frail populations remain areas of active study.
Two additional concepts frame the field. Herd immunity means that high population coverage protects even those who respond poorly or cannot be vaccinated; its erosion (e.g., falling measles coverage) produces resurgent outbreaks. And vaccine hesitancy is recognized by the WHO as a leading global health threat precisely because the diseases it permits are those that vaccines had already made rare — a success that erases its own visible motivation.
3. Vaccination Across the Lifespan
3.1. Childhood Immunization
The collapse of child mortality over the twentieth century — the single largest longevity gain in human history — was substantially vaccine-driven. Historical comparisons in the United States documented reductions of more than 99% in the incidence of measles, mumps, rubella, polio, diphtheria, pertussis, and Haemophilus influenzae type b disease following the introduction of their vaccines (Roush & Murphy, 2007). The evidence for routine childhood immunization is established at a level few interventions approach, and it is the platform on which later-life prevention is built.
3.2. Adult and Older-Adult Vaccines
Several vaccines specifically target proven late-life killers:
- Influenza. Annual vaccination reduces influenza illness and its complications; influenza infection is a documented trigger of myocardial infarction and stroke, and there is a measurable winter spike in cardiovascular events. Efficacy varies with strain match and age, which is the rationale for high-dose and adjuvanted formulations.
- Pneumococcal. Conjugate vaccines protect against invasive pneumococcal disease and vaccine-type pneumonia in adults. The CAPITA trial demonstrated efficacy of a conjugate vaccine against vaccine-type community-acquired pneumonia in older adults, though the effect on all-cause pneumonia was more limited (Bonten et al., 2015).
- Herpes zoster (shingles). The recombinant adjuvanted vaccine is highly effective (above 90% in trials) against shingles and post-herpetic neuralgia; the older live-attenuated vaccine is less effective but was the basis for the dementia findings discussed below.
- RSV. Vaccines against respiratory syncytial virus for older adults were licensed in 2023 and reduce RSV-associated lower respiratory tract disease, a significant cause of hospitalization in the elderly.
- COVID-19. Updated vaccines reduce severe disease, hospitalization, and death, with waning of protection over months requiring periodic revaccination.
3.3. Off-Target Effects: The Shingles-Dementia Signal
A striking line of evidence suggests that some vaccines may have benefits beyond the infection they target. Using a natural experiment — the date-of-birth-based rollout of the live-attenuated zoster vaccine in Wales, which created otherwise-similar comparison groups differing sharply in vaccination probability — researchers used regression discontinuity to show that zoster vaccination reduced the probability of a new dementia diagnosis over seven years by approximately one-fifth, without affecting other common causes of morbidity or mortality (Eyting et al., 2025). The finding was subsequently corroborated in a separate Australian quasi-experiment.
Two mechanistic hypotheses are plausible and not mutually exclusive: reduction of neurotropic herpesvirus reactivation, and non-specific immunomodulatory effects of vaccination. This is emerging evidence. The design is stronger than ordinary observational data, but it remains quasi-experimental, based on one vaccine and specific health systems, and a randomized trial would be required for confirmation. It should not yet be presented as a proven dementia-prevention strategy — but it is one of the most interesting findings in preventive medicine in years.
4. Evidence That Vaccines Prevent More Than Infection
The cleanest randomized evidence that a vaccine changes a hard, non-infectious outcome comes from the IAMI trial. Investigators randomized patients shortly after myocardial infarction to inactivated influenza vaccine or saline placebo. At 12 months, vaccination reduced the composite of all-cause death, myocardial infarction, or stent thrombosis by about 28% (5.3% versus 7.2%), with reductions in all-cause and cardiovascular death (Fröbert et al., 2021). The trial was stopped early because of the COVID-19 pandemic and did not reach its planned sample size, and roughly 13% of the placebo arm crossed over to vaccination — both factors that would bias the result toward the null, making the observed effect notable.
This result supports the concept of vaccination as cardiovascular prevention, via prevention of infection-triggered events and possibly through anti-inflammatory effects. It does not establish that influenza vaccination extends lifespan in the general population, and the mechanisms are incompletely understood — myocardial infarction rates themselves were not significantly reduced. The evidence is best described as established for a post-MI population and hypothesis-generating for broader cardiovascular prevention.
5. Screening: Catching Disease While Curable
Screening aims to detect disease earlier, when treatment is more effective. Its value is not self-evident: a test that finds more disease is only beneficial if earlier treatment changes outcomes, and only if the harms of false positives, overdiagnosis, and overtreatment do not outweigh the gains. The strongest evidence therefore comes from randomized trials with mortality endpoints.
5.1. Colorectal Cancer Screening
Colorectal screening by colonoscopy or stool testing detects and removes precancerous adenomas and finds cancer at earlier stages. Flexible sigmoidoscopy trials showed reductions in incidence and mortality. The NordICC trial, the first large randomized trial of screening colonoscopy, found that a single invitation to colonoscopy reduced colorectal cancer incidence at 10 years but did not significantly reduce colorectal cancer mortality in the intention-to-screen analysis (Bretthauer et al., 2022). Interpretation is complicated by a participation rate of only about 42% in the invited group, dilution by a low event rate, and the long lag before mortality benefit appears; extended follow-up has narrowed the uncertainty. This is a valuable corrective to the assumption that a highly effective-sounding test automatically produces a mortality benefit at the population level.
5.2. Breast and Cervical Screening
Mammography reduces breast-cancer mortality in women aged roughly 50-69 in randomized trials, at the cost of false positives and a debated degree of overdiagnosis of indolent lesions. The balance, and the optimal starting age and interval, remain subjects of legitimate disagreement. Cervical screening — cytology and, increasingly, primary HPV testing — has reduced cervical cancer incidence and mortality substantially. The HPV vaccine adds primary prevention: in a Swedish national cohort, quadrivalent HPV vaccination was associated with a substantially reduced risk of invasive cervical cancer, with the reduction greatest when vaccination occurred at younger ages (Lei et al., 2020).
5.3. Lung Cancer Screening
Lung cancer kills more people than any other cancer, and late-stage disease is usually incurable. The National Lung Screening Trial showed that annual low-dose CT screening in high-risk smokers reduced lung-cancer mortality by 20% relative to chest radiography (NLST Research Team, 2011), at the cost of a high false-positive rate and downstream procedures. The Dutch-Belgian NELSON trial confirmed a substantial lung-cancer mortality reduction using volume-based nodule management, with lower referral rates for indeterminate findings (de Koning et al., 2020). These trials make low-dose CT screening the best-evidenced cancer screening intervention after colorectal screening — but limited to well-defined high-risk populations defined by age and smoking history, not the general population.
5.4. Vascular, Metabolic, and Infectious Screening
Hypertension and lipid screening are cheap, quick, and feed directly into the risk-factor control that adds years of life — among the highest-yield actions in all of preventive medicine. Abdominal aortic aneurysm ultrasound for older men with a smoking history detects a lethal condition at a treatable stage. Hepatitis C testing followed by direct-acting antiviral therapy accomplishes something rare in chronic disease: a cure, with reduced cirrhosis and hepatocellular carcinoma risk. Diabetes screening identifies people in whom lifestyle and pharmacologic intervention demonstrably reduce complications.
6. The Balance of Benefits and Harms
Screening is a trade, not a free good. The relevant harms are well characterized:
- False positives. These generate anxiety and diagnostic cascades — biopsies, imaging, procedures — without benefit. In the NLST, more than 96% of positive low-dose CT results were false positives.
- Overdiagnosis. Detection of lesions that would never have caused symptoms or death, leading to unnecessary treatment. This is the central controversy in prostate and some breast and thyroid screening.
- Lead-time and length-time bias. Earlier diagnosis can make survival appear longer without delaying death, and screening preferentially finds slower-growing tumours.
- Procedure-related harm. Bleeding, perforation, and complications of follow-up testing.
The art of screening is targeting by age and risk: applying tests where the pre-test probability of clinically important, treatable disease is high enough that benefits exceed harms. The same Bayesian arithmetic that constrains cancer screening applies to any test used in a low-prevalence population.
7. Translation to Longevity
At the population level, preventive medicine extends life by a modest margin — on the order of a few years in aggregate, smaller than the effect of smoking cessation — but its strategic function is larger than its average effect. Every prevented infection and every early-caught cancer preserves the option value of future therapies, including regenerative and geroprotective interventions that may arrive within a person’s remaining lifetime. The longevity-minded individual treats the vaccination calendar and the risk-appropriate screening schedule as non-negotiable infrastructure.
It is important not to overstate the case. Vaccines and screening reduce the burden of specific diseases; they do not slow biological aging itself. Their contribution is to compress morbidity and extend healthspan by removing the competing causes of death and disability that would otherwise dominate.
8. Limitations and Open Questions
- Immunosenescence. Efficacy in frail older adults is lower and wanes faster; optimal formulations and schedules are unsettled.
- Off-target effects. The dementia signal from zoster vaccination is promising but quasi-experimental and awaits randomized confirmation.
- Overdiagnosis. Some screening detects disease that would never have harmed the patient, with real treatment-related cost.
- Implementation. Benefit depends on coverage, timeliness, and follow-up; inequities in access persist even where vaccines and tests are free.
- Evidence gaps by population. Most trials were conducted in specific regions and age ranges; generalizability is imperfect.
- Hesitancy and misinformation. Declining coverage threatens the herd immunity that protects the most vulnerable.
9. Future Directions
Vaccines designed for aging immunity. Higher-dose, adjuvanted, and mRNA platforms aim to overcome immunosenescence, with older adults as a specific target population.
Randomized tests of off-target benefits. Trials are being considered to test whether zoster or other vaccination reduces dementia incidence directly, which would convert a compelling quasi-experiment into causal evidence.
Precision screening. Risk models that combine genetics, biomarkers, and imaging may target screening more efficiently than age alone, reducing overdiagnosis.
Multi-cancer early detection. Blood-based multi-cancer tests may complement organ-specific screening, but their stage I sensitivity and population-level benefit remain unproven.
Equity-oriented delivery. Improving coverage in under-served populations delivers larger health gains than marginal improvements in already well-served groups.
10. Conclusion
Vaccination and evidence-based screening remain the most life-years-per-dollar interventions in medicine, and their effect on healthy longevity is large when measured against almost any alternative. The evidence is strongest for routine immunization, childhood vaccines, HPV vaccination, colorectal and lung cancer screening, and risk-factor screening; it is more nuanced for breast and prostate screening, where overdiagnosis requires honest balancing; and it is genuinely exciting but still emerging for vaccine effects on non-infectious diseases such as dementia. The defensible position is neither blind enthusiasm nor reflexive scepticism, but adherence to the vaccination calendar and to risk-appropriate, age-appropriate screening — the routine infrastructure that keeps a person alive and intact long enough for anything else to matter.
Sources and Key Research Centers
- Shattock AJ et al. «Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.» The Lancet, 2024; 403(10441): 2307-2316. DOI: 10.1016/S0140-6736(24)00850-X
- Roush SW, Murphy TV. «Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.» JAMA, 2007; 298(18): 2155-2163. DOI: 10.1001/jama.298.18.2155
- Fröbert O et al. «Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (IAMI).» Circulation, 2021; 144(18): 1476-1484. DOI: 10.1161/CIRCULATIONAHA.121.057042
- Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. «A natural experiment on the effect of herpes zoster vaccination on dementia.» Nature, 2025; 641(8062): 438-446. DOI: 10.1038/s41586-025-08800-x
- Bonten MJM et al. (CAPITA). «Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.» New England Journal of Medicine, 2015; 372(12): 1114-1125. DOI: 10.1056/NEJMoa1408544
- National Lung Screening Trial Research Team (Aberle DR et al.). «Reduced lung-cancer mortality with low-dose computed tomographic screening.» New England Journal of Medicine, 2011; 365(5): 395-409. DOI: 10.1056/NEJMoa1102873
- de Koning HJ et al. (NELSON). «Reduced lung-cancer mortality with volume CT screening in a randomized trial.» New England Journal of Medicine, 2020; 382(6): 503-513. DOI: 10.1056/NEJMoa1911793
- Bretthauer M et al. (NordICC). «Effect of colonoscopy screening on risks of colorectal cancer and related death.» New England Journal of Medicine, 2022; 387(17): 1547-1556. DOI: 10.1056/NEJMoa2208375
- Lei J et al. «HPV vaccination and the risk of invasive cervical cancer.» New England Journal of Medicine, 2020; 383(14): 1340-1348. DOI: 10.1056/NEJMoa1917338
- CDC: Adult and Child Immunization Schedules — Recommended vaccination schedules and efficacy data.
- World Health Organization: Vaccines and Immunization — Global coverage and mortality-averted estimates.
- U.S. Preventive Services Task Force (USPSTF) — Evidence-graded recommendations for clinical preventive services, including cancer and cardiovascular screening.